Kseniia Ievleva

Dr. Kseniia Ievleva

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LSLi Sun
Li Sun
DLDaria Lizneva
Daria Lizneva
YJYaoting Ji
Yaoting Ji
GCGraziana Colaianni
Graziana Colaianni
EHElina Hadelia
Elina Hadelia
MZMone Zaidi
Mone Zaidi
The primitive neurohypophyseal nonapeptide oxytocin (OXT) has established functions in parturition, lactation, appetite, and social behavior. We have shown that OXT has direct actions on the mammalian skeleton, stimulating bone formation by osteoblasts and modulating the genesis and function of bone-resorbing osteoclasts. We deleted OXT receptors (OXTRs) selectively in osteoblasts and osteoclasts using Col2.3Cre and Acp5Cre mice, respectively. Both male and female Col2.3Cre + : Oxtr fl/fl mice recapitulate the low-bone mass phenotype of Oxtr +/− mice, suggesting that OXT has a prominent osteoblastic action in vivo. Furthermore, abolishment of the anabolic effect of estrogen in Col2.3Cre + : Oxtr fl/fl mice suggests that osteoblastic OXTRs are necessary for estrogen action. In addition, the high bone mass in Acp5Cre + : Oxtr fl/fl mice indicates a prominent action of OXT in stimulating osteoclastogenesis. In contrast, we found that in pregnant and lactating Col2.3Cre + : Oxtr fl/fl mice, elevated OXT inhibits bone resorption and rescues the bone loss otherwise noted during pregnancy and lactation. However, OXT does not contribute to ovariectomy-induced bone loss. Finally, we show that OXT acts directly on OXTRs on adipocytes to suppress the white-to-beige transition gene program. Despite this direct antibeiging action, injected OXT reduces total body fat, likely through an action on OXT-ergic neurons. Consistent with an antiobesity action of OXT, Oxt −/− and Oxtr −/− mice display increased total body fat. Overall, the actions of OXT on bone mass and body composition provide the framework for future therapies for osteoporosis and obesity.

30 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SGSakshi Gera
Sakshi Gera
DSDamini Sant
Damini Sant
SHShozeb Haider
Shozeb Haider
FKFunda Korkmaz
Funda Korkmaz
TKTan-Chun Kuo
Tan-Chun Kuo
MZMone Zaidi
Mone Zaidi
Blocking the action of FSH genetically or pharmacologically in mice reduces body fat, lowers serum cholesterol, and increases bone mass, making an anti-FSH agent a potential therapeutic for three global epidemics: obesity, osteoporosis, and hypercholesterolemia. Here, we report the generation, structure, and function of a first-in-class, fully humanized, epitope-specific FSH blocking antibody with a KD of 7 nM. Protein thermal shift, molecular dynamics, and fine mapping of the FSH–FSH receptor interface confirm stable binding of the Fab domain to two of five receptor-interacting residues of the FSHβ subunit, which is sufficient to block its interaction with the FSH receptor. In doing so, the humanized antibody profoundly inhibited FSH action in cell-based assays, a prelude to further preclinical and clinical testing. Significance We report the development and characterization of a first-in-class humanized antibody to follicle-stimulating hormone (FSH). We have shown previously that blocking FSH action on its receptor increases bone mass, reduces body fat, and enhances energy expenditure. Furthermore, FSH has been reported to increase serum cholesterol. Therefore, an anti-FSH agent has the potential of preventing and treating obesity, osteoporosis, and hypercholesterolemia, diseases that affect millions of women and men worldwide. Our study provides the framework for further preclinical and subsequent clinical testing of our humanized antibody to FSH.

20 September 2022 in eLife
Verified
Journal Article
Open access
SGSakshi Gera
Sakshi Gera
TKTan-Chun Kuo
Tan-Chun Kuo
AGAnisa Azatovna Gumerova
Anisa Azatovna Gumerova
FKFunda Korkmaz
Funda Korkmaz
DSDamini Sant
Damini Sant
MZMone Zaidi
Mone Zaidi
Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, and Alzheimer’s disease. Blocking FSH action prevents bone loss, fat gain, and neurodegeneration in mice. We recently developed a first-in-class, humanized, epitope-specific FSH-blocking antibody, MS-Hu6, with a KD of 7.52 nM. Using a Good Laboratory Practice (GLP)-compliant platform, we now report the efficacy of MS-Hu6 in preventing and treating osteoporosis in mice and parameters of acute safety in monkeys. Biodistribution studies using 89Zr-labeled, biotinylated or unconjugated MS-Hu6 in mice and monkeys showed localization to bone and bone marrow. The MS-Hu6 displayed a β phase t½ of 7.5 days (180 hr) in humanized Tg32 mice. We tested 217 variations of excipients using the protein thermal shift assay to generate a final formulation that rendered MS-Hu6 stable in solution upon freeze-thaw and at different temperatures, with minimal aggregation, and without self-, cross-, or hydrophobic interactions or appreciable binding to relevant human antigens. The MS-Hu6 showed the same level of “humanness” as human IgG1 in silico and was non-immunogenic in ELISpot assays for IL-2 and IFN-γ in human peripheral blood mononuclear cell cultures. We conclude that MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for future human testing.

8 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Se Min KimSe Min Kim
Se Min Kim
CTCharit Taneja
Charit Taneja
HPHelena Pérez Peña
Helena Pérez Peña
VRVitaly Ryu
Vitaly Ryu
AGAnisa Gumerova
Anisa Gumerova
MZMone Zaidi
Mone Zaidi
Significance: Tadalafil and vardenafil are among the most widely used drugs for erectile dysfunction, which affects nearly 19% of men over 20 y of age. Older men also suffer from age-related bone loss resulting in crippling fractures. We show that in mice, both agents act on bone cells, resulting in the formation of new bone and reduced removal of old bone. Because of this net gain in bone mass, we posit that tadalafil and vardenafil could be used for cotreating erectile dysfunction and osteoporosis in men of advancing age, as well as for treating osteoporosis in postmenopausal women. We recommend future clinical studies to establish the capability of these drugs to increase bone density and reduce fracture risk in humans.

22 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Larisa SuturinaLarisa Suturina
Larisa Suturina
DLDaria Lizneva
Daria Lizneva
AAAlina Atalyan
Alina Atalyan
LLLyudmila Lazareva
Lyudmila Lazareva
ABAleksey Belskikh
Aleksey Belskikh
RARicardo Azziz
Ricardo Azziz
Androgen assessment is a key element for diagnosing polycystic ovary syndrome (PCOS), and defining a “normal” level of circulating androgens is critical for epidemiological studies. We determined the upper normal limits (UNLs) for androgens in a population-based group of premenopausal “healthy control” women, overall and by ethnicity (Caucasian and Asian), in the cross-sectional Eastern Siberia PCOS Epidemiology and Phenotype (ESPEP) Study (ClinicalTrials.gov ID: NCT05194384) conducted in 2016–2019. Overall, we identified a “healthy control” group consisting of 143 healthy premenopausal women without menstrual dysfunction, hirsutism, polycystic ovaries, or medical disorders. We analyzed serum total testosterone (TT) by using liquid chromatography with tandem mass spectrometry (LC-MS/MS), and DHEAS, sex-hormone-binding globulin (SHBG), TSH, prolactin, and 17-hydroxyprogesterone (17OHP) were assessed with an enzyme-linked immunosorbent assay (ELISA). The UNLs for the entire population for the TT, free androgen index (FAI), and DHEAS were determined as the 98th percentiles in healthy controls as follows: 67.3 (95% confidence interval (CI): 48.1, 76.5) ng/dl, 5.4 (3.5, 14.0), and 355 (289, 371) μg/dl, respectively. The study results demonstrated that the UNLs for TT and FAI varied by ethnicity, whereas the DHEAS UNLs were comparable in the ethnicities studied.

4 July 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Larisa SuturinaLarisa Suturina
Larisa Suturina
ESEldar M. Sharifulin
Eldar M. Sharifulin
MSMaharam A. Sharifulin
Maharam A. Sharifulin
LLLyudmila Lazareva
Lyudmila Lazareva
IDIrina Nikolaevna Danusevich
Irina Nikolaevna Danusevich
INIana Gennadievna Nadeliaeva
Iana Gennadievna Nadeliaeva
Leydig cell tumors (LCTs) refer to tumors of the stroma of the genital strand, which are found mainly in postmenopausal women. The diagnosis of LCTs in postmenopausal women is associated with specific difficulties and is based on the identification of hyperandrogenism with clinical manifestations of virilization, which has an erased picture in postmenopausal women. LCTs require differential diagnosis with other causes of hyperandrogenism. We present the clinical case of a 55-year-old Russian postmenopausal patient with LCTs of the right ovary, significantly increased levels of androgens, and rapidly progressive clinical signs of hyperandrogenism. The patient underwent laparoscopic bilateral salpingo-oophorectomy, and the androgen indices reached average values by the first and third month after surgery. This case demonstrates that LCTs are often benign with a good prognosis and normalization of the clinical and laboratory manifestations of hyperandrogenism after surgical treatment. The type of surgery performed (bilateral salpingo-oophorectomy rather than unilateral) is recommended as the treatment of choice for LCTs in postmenopausal patients.